Recurrent Diffuse Large B-Cell Lymphoma Clinical Trials

19 studies are recruiting for recurrent diffuse large b-cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

   This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetosta…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Banner University Medical Center - Tucson, Tucson, Arizona

   Locations

   104 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05890352 on ClinicalTrials.gov

2. Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

   This phase II studies how well natalizumab works in preventing immune effector cell associated neurologic syndrome (ICANS) in patients with diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) that has come back after a period of improvement (recurrent) or that does not respond to tr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT07892027 on ClinicalTrials.gov

3. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

   This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (re…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   114 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06649812 on ClinicalTrials.gov

4. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

   This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Banner University Medical Center - Tucson, Tucson, Arizona

   Locations

   95 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05633615 on ClinicalTrials.gov

5. Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

   This phase I trial tests the safety, side effects, and best dose of total body irradiation (TBI) in combination with standard of care lymphodepletion with cyclophosphamide and fludarabine before tisagenlecleucel (Tisa-cel) and how well the combination works in patients with large B-cell lymphoma (L…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Nathan Denlinger

   See if you can join NCT07676877 on ClinicalTrials.gov

6. Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

   This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal anti…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05672251 on ClinicalTrials.gov

7. Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma

   The goal of this clinical trial is to reduce the duration of ICANS and incidence of G3 or great ICANS in participants who receive axi-cel. The main questions the study aims to answer are: Efficacy of IT therapy to reduce high-grade ICANS in participants who receive axi-cel in NHL compared to histor…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT07763210 on ClinicalTrials.gov

8. Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

   This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Locations

   4 in total

   Run by

   Mayo Clinic

   See if you can join NCT03418038 on ClinicalTrials.gov

9. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

   This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   9 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05272384 on ClinicalTrials.gov

10. Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

    This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refract…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT06784726 on ClinicalTrials.gov

11. Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

    This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a bispecific antibody,…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota

    Locations

    3 in total

    Run by

    Yazeed Sawalha

    See if you can join NCT06536049 on ClinicalTrials.gov

12. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

    This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Comprehensive Cancer Center, Duarte, California

    Locations

    7 in total

    Run by

    AIDS Malignancy Consortium

    See if you can join NCT05077527 on ClinicalTrials.gov

13. Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

    This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapy in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previ…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT06854159 on ClinicalTrials.gov

14. Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

    This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X] or gemcitabine and oxaliplatin [Gem/Ox]) and autolog…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT06905509 on ClinicalTrials.gov

15. Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT06859008 on ClinicalTrials.gov

16. Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

    This phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) with exposure to high-risk antibiotics who are receivi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT07042438 on ClinicalTrials.gov

17. Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

    This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patients with high grade B-cell non-Hodgkin lymphoma. …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT05432635 on ClinicalTrials.gov

18. B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

    This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematologic malignancies that has come back after a peri…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT06191887 on ClinicalTrials.gov

19. Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

    This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) or has not responded to previous treatment (refractory). Patients with relapsed or refractory disea…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT05800405 on ClinicalTrials.gov